Abstracts Archive - Page 850 of 2425 - ACR Meeting Abstracts

Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 1377 • 2019 ACR/ARP Annual Meeting
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
Vibeke Strand¹, Janet Pope ², John Woolcott ³, Jose L. Rivas ⁴, Annette Diehl ³, Shixue Liu ⁵, David Gruben ⁶ and Stanley Cohen ⁷, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Western University, London, ON, Canada, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Shanghai, China (People's Republic), ⁶Pfizer Inc, Groton, CT, ⁷Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib +/- background MTX has been shown to be an effective treatment…
Abstract Number: 1378 • 2019 ACR/ARP Annual Meeting
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
Vibeke Strand¹, Jerome Msihid ², Toshio Kimura ³, Anita Boyapati ³, Gregory St John ⁴ and Wenhui Wei ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Sanofi, Chilly-Mazarin, France, ³Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients. However,…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Robin Dore¹, Jenya Antonova ², Leslie Harrold ³, Lawrence Chang ², Emily Scherer ⁴, Angel Cronin ⁵, Kelechi Emeanuru ⁵ and Joel Kremer ⁶, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC, Cambridge, MA, ⁵Corrona, LLC, Waltham, MA, ⁶Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 1382 • 2019 ACR/ARP Annual Meeting
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Jacob Greenmyer ¹, John Stacy ¹, James Beal ², Abe Sahmoun ² and Erdal Diri¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Glucocorticoids (GCs) are commonly used in RA patients as remission induction monotherapy or as bridging therapy when starting DMARD/biologic therapy. Despite the ubiquity of…
Abstract Number: 1383 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
Frank Buttgereit¹, J. Michael Nebesky ², Gerd Burmester ³, Corrado Bernasconi ², Markus R. John ² and Marc Y. Donath ⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴University Hospital Basel, Basel, Switzerland
Background/Purpose: Systemic glucocorticoids (GCs) are used to treat serious inflammatory diseases but are associated with adverse events. Guidelines recommend tapering GCs to the lowest possible…
Abstract Number: 1384 • 2019 ACR/ARP Annual Meeting
Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort
Kathleen M Andersen¹, Orit Schieir ², Marie-France Valois ³, Susan J. Bartlett ⁴, Louis Bessette ⁵, Gilles Boire ⁶, Glen Hazlewood ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Diane Tin ¹¹, Carter Thorne ¹², Vivian Bykerk ¹³ and Canadian Early Arthritis Cohort (CATCH) Investigators ¹⁴, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Laval University, Quebec City, QC, Canada, ⁶Sherbrooke University, Sherbrooke, QC, Canada, ⁷University of Calgary, Calgary, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Hospital for Special Surgery, New York City, NY, ¹⁴Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are recommended for and commonly used in rheumatoid arthritis (RA) as initial “bridge therapy”, acting to rapidly reduce the inflammatory response…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1386 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Leslie Harrold¹, Ying Shan ², Sabrina Rebello ², Lin Guo ², Sean Connolly ³, Joe Zhuo ³, Sheila Kelly ³ and Thomas Lehman ³, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: In a US national observational study conducted in a clinical practice setting, patients who were positive (+) for anti-cyclic citrullinated peptide (CCP) antibodies at…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1388 • 2019 ACR/ARP Annual Meeting
The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM
Qian Xia ¹, Xue Han², Ying Bao ¹, Vardhaman Patel ³, Varshini Rajagopalan ⁴ and Francis Lobo ², ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Bristol-Myers Squibb, New York City, NY, ⁴Mu-Sigma, Bengaluru, India
Background/Purpose: Type 2 diabetes mellitus (T2DM)-related complications are costly, and there is lack of information regarding the comparative impact of target disease-modifying anti-rheumatic drugs (tDMARDs)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].